172 related articles for article (PubMed ID: 17244226)
1. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure.
Kernt M; Neubauer AS; Kampik A
Acta Ophthalmol Scand; 2007 Feb; 85(1):119-20. PubMed ID: 17244226
[No Abstract] [Full Text] [Related]
2. Re: Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin).
Utman SA; Dhillon B
Retina; 2008 Apr; 28(4):667; author reply 667-8. PubMed ID: 18398378
[No Abstract] [Full Text] [Related]
3. Intravitreous bevacizumab and blood pressure: does 'safe' mean 'safe enough'?
Ziemssen F; Folprecht G; Ziemssen T
Acta Ophthalmol Scand; 2007 Aug; 85(5):573-4; author reply 574-5. PubMed ID: 17474969
[No Abstract] [Full Text] [Related]
4. The effects of intravitreal ophthalmic medications on intraocular pressure.
Wu H; Chen TC
Semin Ophthalmol; 2009; 24(2):100-5. PubMed ID: 19373694
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection.
Lee K; Yang H; Lim H; Lew HM
Retina; 2009; 29(10):1409-17. PubMed ID: 19816242
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal triamcinolone after intravitreal bevacizumab for retinal vein occlusions.
Jonas JB; Libondi T; Schlichtenbrede F; Schmidbauer M
Acta Ophthalmol; 2010 Mar; 88(2):e24-5. PubMed ID: 19493250
[No Abstract] [Full Text] [Related]
7. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin).
Falkenstein IA; Cheng L; Freeman WR
Retina; 2007 Oct; 27(8):1044-7. PubMed ID: 18040242
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
Kumar V; Ghosh B; Raina UK; Goel N
Acta Ophthalmol; 2010 Mar; 88(2):e3; author reply e4. PubMed ID: 19549100
[No Abstract] [Full Text] [Related]
9. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy.
Liu L; Wu WC; Yeung L; Wang NK; Kuo YH; Chao AN; Chen KJ; Chen TL; Lai CC; Hwang YS; Chen YP
Ophthalmic Surg Lasers Imaging; 2010; 41(1):72-7. PubMed ID: 20128573
[TBL] [Abstract][Full Text] [Related]
10. Herpetic epithelial keratitis after intravitreal injection of bevacizumab.
Sakarya Y; Sakarya R; Yildirim A
Cornea; 2010 Jul; 29(7):840; author reply 840. PubMed ID: 20574238
[No Abstract] [Full Text] [Related]
11. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for corneal neovascularization.
Jacobs DS; Lim M; Carrasquillo KG; Rosenthal P
Ophthalmology; 2009 Mar; 116(3):592-3; author reply 593-4. PubMed ID: 19264217
[No Abstract] [Full Text] [Related]
13. Charles Bonnet syndrome (visual hallucinations) after intravitreal avastin injection for age-related macular degeneration.
Tan CS; Sanjay S; Au Eong KG
Am J Ophthalmol; 2007 Aug; 144(2):330; author reply 330-1. PubMed ID: 17659977
[No Abstract] [Full Text] [Related]
14. Monitoring systemic complications of intraocular medications.
Pulido JS
Can J Ophthalmol; 2010 Jun; 45(3):215-7. PubMed ID: 20628419
[No Abstract] [Full Text] [Related]
15. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.
Rensch F; Spandau UH; Wickenhäuser A; Jonas JB
Acta Ophthalmol; 2010 Mar; 88(2):e36-7. PubMed ID: 19210330
[No Abstract] [Full Text] [Related]
16. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
Ozkiriş A
Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
[TBL] [Abstract][Full Text] [Related]
17. Reflux after intravitreal injection of bevacizumab.
Boon CJ; Crama N; Klevering BJ; van Kuijk FJ; Hoyng CB
Ophthalmology; 2008 Jul; 115(7):1270; author reply 1271. PubMed ID: 18598829
[No Abstract] [Full Text] [Related]
18. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
[TBL] [Abstract][Full Text] [Related]
19. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
Ronan SM; Yoganathan P; Chien FY; Corcóstegui IA; Blumenkranz MS; Deramo VA; Elner SG; Fastenberg DA; Johnson MW; López M; Mateo C; Moshfeghi DM; Navarro R; Rosenblatt BJ; Sanislo SR; Saxe SJ; Zacks DN
Retina; 2007 Jun; 27(5):535-40. PubMed ID: 17558313
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab: the need for controlled studies to move forward.
Buys YM
Can J Ophthalmol; 2007 Dec; 42(6):789. PubMed ID: 18059506
[No Abstract] [Full Text] [Related]
[Next] [New Search]
